Skip to main content
ClinicalTrials.govcontrolled

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

ClinicalTrials.gov study NCT00099437. IPD Sharing: YES. Countries: 17. Publications: 1.

ShareScore

36/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
12
Access
4
Reuse readiness
0
Engagement
8

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-YES
DOI
clinicaltrials.gov/NCT00099437

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.